Vol. 21/No. 23

TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.

Insurance companies are beginning to indirectly manage prescribing to better manage costs.

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

Having patients go on drug holidays or intermittent therapy is a common strategy during treatment of prostate cancer and several other malignancies, whether to provide temporary relief from adverse effects influencing quality of life, to prevent long-term health impacts, or to lessen drug resistance that would render the therapy ineffective.

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.